ArticlePloS one2025
MAGNET-seq: A tandem PCR and hybrid capture method for enhanced target enrichment.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hybrid-capture based target enrichment and multiplex PCR methods enhance sequencing efficiency by focusing on specific genomic regions, while struggling to enrich tens of regions spanning hundreds to thousands of base pairs. We developed MAGNET-seq (Multiplex Amplification and tarGeted eNrichment of sElecTed sequences), a streamlined method that integrates targeted multiplex PCR with hybrid capture. We evaluated its performance using two primer sets: a Drug Resistance Targeting Primers with 43 targets and a Reference Primers set with 7 targets, including clinically relevant mutations such as EGFR c.2369C > T (p.T790M) and KRAS c.35G > T (p.G12C). Using a set of 43 target primers, MAGNET-seq demonstrated higher on-target ratios (average 86.2%) compared to standard targeted multiplex PCR (average 2.2%). Furthermore, MAGNET-seq with 7 target primers showed concordant variant allele frequencies (VAF) in low-VAF (≤ 1%) reference cell-free DNA (cfDNA) samples (0.05% to 1%), supporting its reproducibility. This approach provides a simplified and cost-efficient solution for targeted sequencing, particularly well-suited for applications that require detection of low-allele frequency variants such as somatic cancer mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.